Park Chae Gyu, Lee Sue Hyun, Chu Min Kyung
Heart-Immune-Brain Network Research Center, Department of Life Science, Ewha Womans University, Seoul, Republic of Korea.
Laboratory of Immunology, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Front Neurol. 2022 Oct 12;13:1021065. doi: 10.3389/fneur.2022.1021065. eCollection 2022.
The levels of some migraine biomarkers differ between episodic migraine (EM) and chronic migraine (CM), but information on C-reactive protein (CRP) levels in EM and CM is conflicting. Thus, this study aimed to evaluate CRP levels in participants with EM and CM in comparison to those in healthy controls.
Plasma CRP levels were evaluated by high-sensitivity CRP tests in female participants with EM ( = 174) and CM ( = 191) and healthy controls ( = 50).
The results showed no significant difference in CRP levels among the EM, CM, and control groups (median and interquartile range, 0.40 [0.15-0.70] mg/L vs. 0.40 [0.15-1.00] mg/L vs. 0.15 [0.15-0.90] mg/L, = 0.991). The ratio of individuals with elevated CRP levels (>3.0 mg/L) did not significantly differ among the EM, CM, and control groups (3.4% [6/174] vs. 2.1% [4/191] vs. 0.0% [0/50], = 0.876). Multivariable regression analyses revealed that CRP levels were not significantly associated with headache frequency per month (β = -0.076, = 0.238), the severity of anxiety (Generalized Anxiety Disorder-7 score, β = 0.143, = 0.886), and depression (Patient Health Questionnaire-9 score, β = 0.143, = 0.886). Further, CRP levels did not significantly differ according to clinical characteristics, fibromyalgia, medication overuse, preventive treatment, and classes of preventive treatment medications. Among participants with a body mass index ≥25 kg/m, the CRP levels in EM ( = 41) and CM ( = 17) were numerically higher than those in the control ( = 6) (1.30 [0.28-4.25] mg/L vs. 1.10 [0.50-3.15] mg/L vs. 0.40 [0.15-0.83] mg/L, = 0.249) but did not reach statistical significance.
The interictal CRP level is not likely to be a biomarker for EM or CM.
发作性偏头痛（EM）和慢性偏头痛（CM）患者的某些偏头痛生物标志物水平存在差异，但关于EM和CM中C反应蛋白（CRP）水平的信息相互矛盾。因此，本研究旨在评估EM和CM患者与健康对照者的CRP水平。
通过高敏CRP检测评估174例EM女性患者、191例CM女性患者和50例健康对照者的血浆CRP水平。
结果显示，EM组、CM组和对照组的CRP水平无显著差异（中位数和四分位间距，0.40[0.15 - 0.70]mg/L对0.40[0.15 - 1.00]mg/L对0.15[0.15 - 0.90]mg/L，P = 0.991）。CRP水平升高（>3.0mg/L）的个体比例在EM组、CM组和对照组之间无显著差异（3.4%[6/174]对2.1%[4/191]对0.0%[0/50]，P = 0.876）。多变量回归分析显示，CRP水平与每月头痛频率（β = -0.076，P = 0.238）、焦虑严重程度（广泛性焦虑障碍-7评分，β = 0.143，P = 0.886）和抑郁（患者健康问卷-9评分，β = 0.143，P = 0.886）均无显著相关性。此外，根据临床特征、纤维肌痛、药物过度使用、预防性治疗及预防性治疗药物类别，CRP水平无显著差异。在体重指数≥25kg/m²的参与者中，EM组（n = 41）和CM组（n = 17）的CRP水平在数值上高于对照组（n = 6）（1.30[0.28 - 4.25]mg/L对1.10[0.50 - 3.15]mg/L对0.40[0.15 - 0.83]mg/L，P = 0.249）但未达到统计学意义。
发作间期CRP水平不太可能是EM或CM的生物标志物。
